Immunitybio Total Other Income Expense Net from 2010 to 2024

IBRX Stock  USD 4.97  0.07  1.39%   
Immunitybio Total Other Income Expense Net yearly trend continues to be fairly stable with very little volatility. Total Other Income Expense Net is likely to outpace its year average in 2024. During the period from 2010 to 2024, Immunitybio Total Other Income Expense Net regression line of annual values had r-squared of  0.49 and arithmetic mean of (36,638,927). View All Fundamentals
 
Total Other Income Expense Net  
First Reported
2015-06-30
Previous Quarter
-35.3 M
Current Value
-5.5 M
Quarterly Volatility
25.5 M
 
Yuan Drop
 
Covid
Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.8 M, Interest Expense of 135.7 M or Selling General Administrative of 91.7 M, as well as many indicators such as Price To Sales Ratio of 6.7 K, Dividend Yield of 0.0 or Days Sales Outstanding of 1.8 K. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.
  
Check out the analysis of Immunitybio Correlation against competitors.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Latest Immunitybio's Total Other Income Expense Net Growth Pattern

Below is the plot of the Total Other Income Expense Net of Immunitybio over the last few years. It is Immunitybio's Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunitybio's overall financial position and show how it may be relating to other accounts over time.
Total Other Income Expense Net10 Years Trend
Slightly volatile
   Total Other Income Expense Net   
       Timeline  

Immunitybio Total Other Income Expense Net Regression Statistics

Arithmetic Mean(36,638,927)
Geometric Mean3,014,232
Coefficient Of Variation(204.67)
Mean Deviation51,769,749
Median(609,000)
Standard Deviation74,988,568
Sample Variance5623.3T
Range223.3M
R-Value(0.70)
Mean Square Error3092T
R-Squared0.49
Significance0
Slope(11,730,683)
Total Sum of Squares78726T

Immunitybio Total Other Income Expense Net History

2024-210.6 M
2023-221.6 M
2022-66 M
2021-19.6 M
2020-25.4 M
2019-4 M
2018-433 K

About Immunitybio Financial Statements

Immunitybio investors use historical fundamental indicators, such as Immunitybio's Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Other Income Expense Net-221.6 M-210.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.